The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation.

The Biopharmaceutical Classification System (BCS) guidance issued by the FDA allows waivers for in vivo bioavailability and bioequivalence studies for immediate-release (IR) solid oral dosage forms only for BCS class I drugs. However, a number of drugs within BCS class III have been proposed to be eligible for biowaivers. The World Health Organization (WHO) has shortened the requisite dissolution time of BCS class III drugs on their Essential Medicine List (EML) from 30 to 15 min for extended biowaivers; however, the impact of the shorter dissolution time on AUC(0-inf) and C(max) is unknown. The objectives of this investigation were to assess the ability of gastrointestinal simulation software to predict the oral absorption of the BCS class I drugs propranolol and metoprolol and the BCS class III drugs cimetidine, atenolol, and amoxicillin, and to perform in silico bioequivalence studies to assess the feasibility of extending biowaivers to BCS class III drugs. The drug absorption from the gastrointestinal tract was predicted using physicochemical and pharmacokinetic properties of test drugs provided by GastroPlus (version 6.0). Virtual trials with a 200 mL dose volume at different drug release rates (T(85%) = 15 to 180 min) were performed to predict the oral absorption (C(max) and AUC(0-inf)) of the above drugs. Both BCS class I drugs satisfied bioequivalence with regard to the release rates up to 120 min. The results with BCS class III drugs demonstrated bioequivalence using the prolonged release rate, T(85%) = 45 or 60 min, indicating that the dissolution standard for bioequivalence is dependent on the intestinal membrane permeability and permeability profile throughout the gastrointestinal tract. The results of GastroPlus simulations indicate that the dissolution rate of BCS class III drugs could be prolonged to the point where dissolution, rather than permeability, would control the overall absorption. For BCS class III drugs with intestinal absorption patterns similar to those of cimetidine, atenolol or amoxicillin, the dissolution criteria for extension of biowaivers to BCS class III drugs warrants further investigation.

[1]  A. Parr,et al.  Effect of Sodium Acid Pyrophosphate on Ranitidine Bioavailability and Gastrointestinal Transit Time , 1993, Pharmaceutical Research.

[2]  M. I. Maguregui,et al.  Determination of the pKa values of beta-blockers by automated potentiometric titrations. , 2000, Journal of pharmaceutical and biomedical analysis.

[3]  D. Barends,et al.  Biowaiver monographs for immediate release solid oral dosage forms: cimetidine. , 2006, Journal of pharmaceutical sciences.

[4]  N. Davies Clinical Pharmacokinetics of Flurbiprofen and its Enantiomers , 1995, Clinical pharmacokinetics.

[5]  P. Routledge,et al.  Clinical Pharmacokinetics of Propranolol , 1979, Clinical pharmacokinetics.

[6]  Brian R. Phillips,et al.  INTERACTIONS OF AMOXICILLIN AND CEFACLOR WITH HUMAN RENAL ORGANIC ANION AND PEPTIDE TRANSPORTERS , 2006, Drug Metabolism and Disposition.

[7]  S. Stavchansky,et al.  Estimation of the Relative Contribution of the Transcellular and Paracellular Pathway to the Transport of Passively Absorbed Drugs in the Caco-2 Cell Culture Model , 1997, Pharmaceutical Research.

[8]  G. Amidon,et al.  The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests. , 2006, Molecular pharmaceutics.

[9]  Jack A. Cook,et al.  Summary Workshop Report: Bioequivalence, Biopharmaceutics Classification System, and Beyond , 2008, The AAPS Journal.

[10]  Lawrence X. Yu,et al.  Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[11]  S. Stavchansky Scientific Perspectives on Extending the Provision for Waivers of In vivo Bioavailability and Bioequivalence Studies for Drug Products Containing High Solubility-Low Permeability Drugs (BCS-Class 3) , 2008, The AAPS Journal.

[12]  Peter Langguth,et al.  An Investigation into the Importance of “Very Rapid Dissolution” Criteria for Drug Bioequivalence Demonstration using Gastrointestinal Simulation Technology , 2009, The AAPS Journal.

[13]  R. Mehvar,et al.  Pharmacokinetics of atenolol enantiomers in humans and rats. , 1990, Journal of pharmaceutical sciences.

[14]  D. Barends,et al.  Biowaiver monographs for immediate release solid oral dosage forms: ethambutol dihydrochloride. , 2008, Journal of pharmaceutical sciences.

[15]  Lawrence X. Yu,et al.  A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. , 2006, Molecular pharmaceutics.

[16]  A. Rane,et al.  Increased oral clearance of metoprolol in pregnancy , 2004, European Journal of Clinical Pharmacology.

[17]  A. Urtti,et al.  Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[18]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[19]  G. Amidon,et al.  Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. , 2004, Molecular pharmaceutics.

[20]  Ajaz S. Hussain,et al.  The Effect of In Vivo Dissolution, Gastric Emptying Rate, and Intestinal Transit Time on the Peak Concentration and Area-Under-the-Curve of Drugs with Different Gastrointestinal Permeabilities , 2004, Pharmaceutical Research.

[21]  R. Ogilvie,et al.  Pharmacokinetics of amoxicillin , 1974, Clinical pharmacology and therapeutics.

[22]  A. Grahnén Cimetidine bioavailability and variable renal clearance , 2004, European Journal of Clinical Pharmacology.

[23]  G L Amidon,et al.  The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. , 1990, Gastroenterology.

[24]  R. Neubert,et al.  Intestinal Transport of β-Lactam Antibiotics: Analysis of the Affinity at the H+/Peptide Symporter (PEPT1), the Uptake into Caco-2 Cell Monolayers and the Transepithelial Flux , 2004, Pharmaceutical Research.

[25]  D. Barends,et al.  Biowaiver monographs for immediate release solid oral dosage forms: aciclovir. , 2008, Journal of pharmaceutical sciences.

[26]  G L Amidon,et al.  Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. , 2004, Journal of pharmaceutical sciences.

[27]  L. Benet,et al.  Active secretion and enterocytic drug metabolism barriers to drug absorption. , 2001, Advanced drug delivery reviews.

[28]  Vinod P. Shah,et al.  Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions , 2002, Pharmaceutical Research.

[29]  B. Schug,et al.  The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver? , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[30]  D. Barends,et al.  Review of global regulations concerning biowaivers for immediate release solid oral dosage forms. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[31]  Jennifer B Dressman,et al.  Feasibility of Biowaiver Extension to Biopharmaceutics Classification System Class III Drug Products , 2006, Clinical Pharmacokinetics.

[32]  K Ojala,et al.  Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs. , 2010, Journal of pharmaceutical sciences.

[33]  H. Lode,et al.  Changes in fecal flora and comparative multiple-dose pharmacokinetics of ceftibuten, cefpodoxime proxetil and amoxycillin/clavulanate. , 1999, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[34]  Mehran Yazdanian,et al.  The “High Solubility” Definition of the Current FDA Guidance on Biopharmaceutical Classification System May Be Too Strict for Acidic Drugs , 2004, Pharmaceutical Research.